1492 Capital Management LLC reduced its holdings in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 1.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 778,483 shares of the specialty pharmaceutical company’s stock after selling 7,520 shares during the period. BioDelivery Sciences International makes up 3.2% of 1492 Capital Management LLC’s portfolio, making the stock its 5th largest holding. 1492 Capital Management LLC owned approximately 0.87% of BioDelivery Sciences International worth $3,277,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Russell Investments Group Ltd. grew its stake in shares of BioDelivery Sciences International by 3.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 86,390 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 3,160 shares in the last quarter. Rhumbline Advisers grew its stake in shares of BioDelivery Sciences International by 4.6% in the 3rd quarter. Rhumbline Advisers now owns 87,670 shares of the specialty pharmaceutical company’s stock worth $369,000 after buying an additional 3,851 shares in the last quarter. BTR Capital Management Inc. purchased a new position in shares of BioDelivery Sciences International in the 2nd quarter worth $47,000. Cutter & CO Brokerage Inc. purchased a new position in shares of BioDelivery Sciences International in the 2nd quarter worth $60,000. Finally, NEXT Financial Group Inc grew its stake in shares of BioDelivery Sciences International by 17.0% in the 2nd quarter. NEXT Financial Group Inc now owns 135,350 shares of the specialty pharmaceutical company’s stock worth $629,000 after buying an additional 19,700 shares in the last quarter. 66.54% of the stock is owned by institutional investors and hedge funds.

In other news, Director Mark A. Sirgo sold 103,321 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $4.98, for a total transaction of $514,538.58. Following the completion of the sale, the director now directly owns 1,703,124 shares of the company’s stock, valued at approximately $8,481,557.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 157,177 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $4.79, for a total value of $752,877.83. Following the sale, the director now directly owns 1,874,637 shares of the company’s stock, valued at $8,979,511.23. The disclosure for this sale can be found here. Insiders have sold a total of 373,364 shares of company stock valued at $1,859,559 over the last ninety days. Company insiders own 8.94% of the company’s stock.

BioDelivery Sciences International stock opened at $5.79 on Friday. BioDelivery Sciences International, Inc. has a 12-month low of $2.80 and a 12-month high of $6.12. The firm has a 50-day moving average price of $5.08 and a 200-day moving average price of $4.56. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $519.23 million, a PE ratio of -7.93 and a beta of 0.39.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. The company had revenue of $29.68 million during the quarter, compared to the consensus estimate of $25.30 million. As a group, sell-side analysts predict that BioDelivery Sciences International, Inc. will post -0.05 earnings per share for the current fiscal year.

A number of equities analysts have commented on BDSI shares. BidaskClub cut shares of BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research note on Friday. William Blair reissued a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 17th. Finally, ValuEngine upgraded shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 29th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $6.20.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: What is Cost of Debt?

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.